Dr John Charles Gordon, MD | |
6830 Hospital Drive #202, Baltimore, MD 21237-4377 | |
(410) 575-0077 | |
(410) 574-0884 |
Full Name | Dr John Charles Gordon |
---|---|
Gender | Male |
Speciality | Orthopaedic Surgery |
Location | 6830 Hospital Drive #202, Baltimore, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1669557526 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207X00000X | Orthopaedic Surgery | D14268 (Maryland) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr John Charles Gordon, MD 6830 Hospital Drive #202, Baltimore, MD 21237-4377 Ph: (410) 575-0077 | Dr John Charles Gordon, MD 6830 Hospital Drive #202, Baltimore, MD 21237-4377 Ph: (410) 575-0077 |
News Archive
The former president - dubbed the "explainer in chief" - spoke from his presidential library in Arkansas to drum up support for the overhaul and scold Republicans for their efforts to repeal it.
Patients treated with more-invasive surgical techniques for a type of early-stage lung cancer are more likely to become chronic opioid users than patients treated with minimally invasive surgery, highlighting the need for additional research into how pain management after surgery might be a contributing factor to the opioid addiction crisis, according to a study published in JAMA Oncology in September.
A recent study by researchers from the United Kingdom (UK) revealed that antibody levels associated with protection against reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are likely to last from 1.5 to 2 years on average and that the protection from severe infection may be present for several years.
Janssen-Cilag International NV today announced that data from a post-hoc analysis of the Phase 3 COU-AA-302 trial showed that ZYTIGA (abiraterone acetate) plus prednisone provided an 11.8 months overall survival (OS) benefit (53.6 months vs 41.8 months; HR = 0.61 [95% CI, 0.43-0.87]; p = 0.0055), compared to an active control of placebo plus prednisone, in men with early and less aggressive chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).
› Verified 3 days ago
Robert J Brumback, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 3333 North Calvert Street, Suite 400, Baltimore, MD 21218 Phone: 410-554-2270 Fax: 410-261-2726 | |
Dr. Milford Howarth Marchant Jr., M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2900 S Hanover St, Baltimore, MD 21225 Phone: 410-350-8336 Fax: 410-350-7178 | |
Dr. Michelle Ghert, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 110 S Paca St Fl 6, Baltimore, MD 21201 Phone: 614-397-2721 | |
Henry R Boucher, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3333 North Calvert Street, Suite 400, Baltimore, MD 21218 Phone: 410-554-2270 Fax: 410-261-2726 | |
John J Carbone, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 3001 S Hanover St, Gruehn Bldg, Ste 502, Baltimore, MD 21225 Phone: 410-350-8300 | |
Dr. Dawn Laporte, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 601 N Caroline St, Rm 5210, Baltimore, MD 21287 Phone: 410-955-3134 | |
Paul C Mcafee, M.D., MBA Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3333 N Calvert St Ste 655, Baltimore, MD 21218 Phone: 410-554-2175 Fax: 410-554-2917 |